STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1956 by analyst upside · 2026-06-27
ATRA
Atara Biotherapeutics, Inc.
Healthcare · Market Cap $95M · P/E 0x
ANALYST PRICE TARGET
+30.0%
implied upside to consensus target
Current Price $10.51
Consensus Target $13.67
Bull Target $18.0
Bear Target $10.0
Analysts Covering 3
ANALYST CONSENSUS — BUY
Strong Buy
0
Buy
2
Hold
1
Sell
0
52-Week Low $3.92
52-Week High $19.14
YTD Return -40.9%
FUNDAMENTALS
Market Cap $95M
P/E Ratio (TTM) N/A
Forward P/E 8.3x
EPS (TTM) $-1.22
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $23M
Profit Margin -40.9%
52-WEEK RANGE
52-Week Low $3.92
52-Week High $19.14
Current Price $10.51
Bear Target $10.0
Bull Target $18.0
● Now $10.51 ● Target $13.67
TRADING DATA
Avg Volume 1.4M
YTD Return -40.9%
Analyst Count 3
Consensus Buy
Upside to Target +30.0%
Last Updated 2026-06-27

ANALYST SUMMARY

Atara Biotherapeutics, Inc. (ATRA) is currently trading at $10.51 with a Wall Street consensus price target of $13.67, implying potential upside of 30.0% over the next 12 months. 3 analysts currently cover ATRA, with a consensus rating of Buy — 67% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $18.0, while the most cautious has a target of $10.0.

ATRA operates in the Healthcare sector with a market capitalisation of $95M. The stock is down 40.9% year-to-date and is currently trading near the lower end of its 52-week range of $3.92 – $19.14.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for ATRA, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Freedom Broker ↑ Upgrade
Sell → Hold 2026-05-18 Building track record
Canaccord Genuity ↑ Upgrade
Hold → Buy 2026-05-08 Building track record
Freedom Broker ↓ Downgrade
Buy → Sell 2026-01-21 Building track record
Canaccord Genuity ↓ Downgrade
Buy → Hold 2026-01-13 Building track record
Canaccord Genuity — Reiterated
Buy → Buy 2025-12-19 Building track record
Canaccord Genuity — Reiterated
Buy → Buy 2025-03-11 Building track record
HC Wainwright & Co. reit
Neutral → Neutral 2025-01-22 31% win rate (48 calls)
Canaccord Genuity — Reiterated
Buy → Buy 2025-01-17 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →